about
SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalinkThe Interaction Between Statins and Exercise: Mechanisms and Strategies to Counter the Musculoskeletal Side Effects of This Combination TherapyPharmacogenomics of adverse drug reactionsA mechanistic, model-based approach to safety assessment in clinical developmentFlavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol dispositionEvaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design.Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective.Synergistic interaction between genetics and disease on pravastatin dispositionSafety of statins: an updateApplication of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1-Related Variability in Pharmacodynamics of Rosuvastatin.The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.Developmental pharmacogenetics in pediatric rheumatology: utilizing a new paradigm to effectively treat patients with juvenile idiopathic arthritis with methotrexate.The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.The SLCO (former SLC21) superfamily of transporters.A cell-based fascin bioassay identifies compounds with potential anti-metastasis or cognition-enhancing functions.Mechanisms and assessment of statin-related muscular adverse effects.Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.Statin pharmacogenomics: opportunities to improve patient outcomes and healthcare costs with genetic testingPharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins.Molecular mechanisms underlying the effects of statins in the central nervous system.Pharmacogenomics: the genetics of variable drug responses.Dyslipidemia in special ethnic populationsImpact of statin therapy on mortality in patients with sepsis-associated acute respiratory distress syndrome (ARDS) depends on ARDS severity: a prospective observational cohort study.Human Ontogeny of Drug Transporters: Review and Recommendations of the Pediatric Transporter Working GroupAssociation of SLCO1B1 gene polymorphisms with toxicity response of high dose methotrexate chemotherapy in childhood acute lymphoblastic leukemia.Global genetic analyses reveal strong inter-ethnic variability in the loss of activity of the organic cation transporter OCT1.Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutionsCommon nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS studyThe farnesoid X receptor -1G>T polymorphism influences the lipid response to rosuvastatin.Plasma metabolomic profiles enhance precision medicine for volunteers of normal health.Using Literature-Based Discovery to Explain Adverse Drug Effects.Genetic variations and patient-reported quality of life among patients with lung cancerIntracellular drug bioavailability: a new predictor of system dependent drug disposition.Treatment Options for Statin-Associated Muscle Symptoms.Cardiovascular Pharmacogenomics--Implications for Patients With CKD.Molecular mechanisms of statin intoleranceAbundance of Hepatic Transporters in Caucasians: A Meta-Analysis.More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-Mediated Clearances.SLCO1B1 Polymorphisms and Statin-Induced Myopathy.Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.
P2860
Q24598793-56641EC3-2143-4EC3-90B9-D7895123E833Q26771168-F6C8730A-93B5-4C4E-AD01-873C2B925562Q27015820-4BD0ECD0-6081-469C-AFF0-7C4335C9A53EQ28395802-B98B32D4-9F19-4A58-985C-97E2821F27A2Q28475976-1730B528-41FD-4FFA-8565-52EDCA7DF910Q30582571-4C84D255-5A2F-4EBA-BFD8-C778106FAA7FQ30616911-8633410A-9864-4FCA-93E9-05B3AC3285EDQ33786577-4FE52626-4C97-4ED3-9D26-FE1A18929630Q33949312-0EA34CFE-DBD6-43EC-88B7-C0A3C52B066FQ33994570-AEAC35AD-0BF0-4386-9792-B4B6566A07ABQ34216710-233A53E1-24F9-4B15-8D29-C07ACA2D5343Q34219644-A2DC6CB6-3842-46C5-A561-DC4759EC9853Q34276618-60D5F9BF-B3C8-439B-B86F-B751EBB5A152Q34333710-47C5C40C-2982-4976-9371-5D3487331620Q34392217-E871C71A-97A1-4912-B9B7-8153D1DC76F1Q34570995-A243FBBE-188D-4B10-A6AF-08557F714013Q34571070-89E71668-F593-40F2-834C-035ECEDBEB65Q34608646-6C111315-281F-4BF9-A98C-6388C844CE9BQ34680467-E1810EF1-7A43-4A20-891D-D6126C0F9295Q34685463-77F6627D-E0D7-4002-9373-010E5B1793C3Q34976915-5A976E29-461D-4D77-9648-E19A2398794EQ35573543-7DF809C8-2ADD-4882-AB91-8AED0A5A869EQ35649119-5B5E3E5D-A306-4EF6-B7AB-CE23A1B1CC45Q35667919-FFE97121-45C3-42A9-98C4-6985D84E361CQ35791771-FDFD5F50-3BAB-4BE0-B8E3-6AB80A27053DQ35831346-1B5C8E2B-0BB0-4DEF-BC1A-5A6AFD80DCD1Q35915932-98F75DFF-56EB-4541-8E95-4C5D12C74177Q35964012-728349EA-FD7C-4F6C-9650-050720D06895Q36020304-299EFBF2-D624-40B1-90C4-57570082BB26Q36055457-D56E7FEC-0AC8-4200-8178-ECB0F19FCB01Q36056257-8057066E-43CC-42C5-BDD1-8DB92400355CQ36058264-B8E02255-8C7C-43EE-B000-EA1D1C86DF3AQ36287236-CF08B595-9F1C-417D-94D6-CE723CD13FA9Q36294394-920803BF-A38C-4F5C-99F3-EAC12880D37FQ36696635-E0A63ED4-A5E9-498D-B2CC-20B77E2C5782Q36958324-60FF5CF3-294F-4845-86FE-F9E467FB55BBQ37279044-EABBEC72-7F85-4910-B92E-0E61FA2F6BC8Q37394474-919400AC-13B9-4F7A-A57F-52082D79FD3DQ37410969-A8BAE00F-076A-4F85-AB97-35DBE00F4ED5Q37579733-B4406C92-4372-4975-8867-2668B4BE9D36
P2860
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Transporter pharmacogenetics and statin toxicity.
@en
Transporter pharmacogenetics and statin toxicity.
@nl
type
label
Transporter pharmacogenetics and statin toxicity.
@en
Transporter pharmacogenetics and statin toxicity.
@nl
prefLabel
Transporter pharmacogenetics and statin toxicity.
@en
Transporter pharmacogenetics and statin toxicity.
@nl
P2860
P356
P1476
Transporter pharmacogenetics and statin toxicity.
@en
P2860
P304
P356
10.1038/CLPT.2009.197
P407
P50
P577
2009-11-04T00:00:00Z